Please wait a minute...
European Journal of Gynaecological Oncology  2020, Vol. 41 Issue (1): 36-41    DOI: 10.31083/j.ejgo.2020.01.4810
Original Research Previous articles | Next articles
Stem cells in ductal breast cancer: immunohistochemical expression of CD44, CD24, CD133, and ALDH-1 markers in 104 cases
D. Korfias1, *(), J. Contis2, M. Frangou-Plemenou3, K. Gennatas4, A. Kondis5, D. Vlachodimitropoulos6
1 Department of Obstetrics and Gynecology,"Metaxa Anti-Cancer Hospital", Piraeus, Greece
2 Department of Surgery, 2nd Surgical Clinic, Aretaieion University Hospital, Athens, Greece
3 Pathology Department, Aretaieion University Hospital, Athens, Greece
4 Department of Oncology, Athens Medical School, University of Athens, Greece
5 Department of Pathology, Athens Medical School, Athens, Greece
6 Department of Pathology, Athens Medical School, University of Athens, Athens, Greece
Download:  PDF(1877KB)  ( 257 ) Full text   ( 7 )
Export:  BibTeX | EndNote (RIS)      
Abstract  
Objective: The aim of this study was to evaluate the immunohistochemical expression of stem cell markers CD44, CD24, CD133, and ALDH-1 in breast carcinomas and investigate any correlation with stage, degree of tumor differentiation, cell proliferation index, and hormone receptors status. Materials and Methods: One hundred and four cases of invasive ductal breast carcinomas were studied and classified according to grade and stage, hormonal status, and C-erbB2 expression. A semi-automatic Ventana method was used to examine by semi-quantitative method the immunohistochemical expression of anti-CD133, CD24, CD44, and ALDH1 antibodies. Results: CD44, CD24, and ALDH1 markers demonstrated a statistically significant correlation with higher disease stage and triple negative cancers (94%-55.5%). CD133 correlated with triple negative cancers (55.5%). No correlation with other clinical data or tumor differentiation was observed. Conclusion: Triple negative breast cancers express specific stem cell markers responsible for cell/stroma interaction and this is a useful tool in predicting tumor progression and developing specific targeted therapies.
Key words:  Breast cancer      Stem cells      CD44      CD24      CD133      ALDH1     
Published:  15 February 2020     
Fund: 
377177/THALIS Research Grant, University of Athens, Greece (UOA)
*Corresponding Author(s):  D. KORFIAS     E-mail:  dkorfias@gmail.com

Cite this article: 

D. Korfias, J. Contis, M. Frangou-Plemenou, K. Gennatas, A. Kondis, D. Vlachodimitropoulos. Stem cells in ductal breast cancer: immunohistochemical expression of CD44, CD24, CD133, and ALDH-1 markers in 104 cases. European Journal of Gynaecological Oncology, 2020, 41(1): 36-41.

URL: 

https://ejgo.imrpress.com/EN/10.31083/j.ejgo.2020.01.4810     OR     https://ejgo.imrpress.com/EN/Y2020/V41/I1/36

[1] Polyana Barbosa Silva, Millena Prata Jammal, Márcia Antoniazi Michelin, Eddie Fernando Cândido Murta. Phenotypic differences of tecidual TDCs obtained from breast cancer mice[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 689-698.
[2] Huifen Zhen, Fan Guo, Xiaojun Zhang, Miaomiao Jia, Haibo Yang, Yarong Yao, Yuandong Li, Jinnan Gao. The effects of chemotherapy with anthracyclines vs capecitabine on tumour size, survival rate and estradiol levels in patients with locally advanced breast cancer[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 785-789.
[3] Katselashvili Lika, Jokhadze Natia, Katcharava Margarita, Vardiashvili Nino. Breast Cancer Metastatic to Vulva - a Case Report[J]. European Journal of Gynaecological Oncology, 2020, 41(5): 845-848.
[4] Hayal Uzelli Şimşek, Turgay Şimşek, Deniz Şahin, Sertaç Ata Güler, Nuh Zafer Cantürk, Nihat Zafer Utkan. Evaluation of the effect of surgical timing on systemic response to trauma in premenopausal patients by using cytokine levels[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 577-582.
[5] Isao Otsuka. Clear cell carcinoma of the vagina followed by breast cancer in a patient without prenatal diethylstilbestrol exposure[J]. European Journal of Gynaecological Oncology, 2020, 41(4): 638-639.
[6] Luca Roncati, Maria Vadalà, Pepe Valentina, Veronica Corazzari, Beniamino Palmieri. Genomic profiling in gynaecological oncology: the future is now![J]. European Journal of Gynaecological Oncology, 2020, 41(3): 323-325.
[7] A. Conversano, C. Balleyguier, M.K. De Fremicourt, H. Alkhashnam, C. Mazouni, J. Arfi-Rouche, N. Leymarie, F. Rimareix. Magnetic seed localisation for non-palpable lesions in patients undergoing breast conservative surgery[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 48-53.
[8] S.Wang, W.J. Chen, Z.M. Song, Q. Li, X. Shen, Y.D. Wu, L. Zhu, Q.X. Ma, D.M. Xing. Long non-coding RNA ROR accelerates the progression of breast cancer via promoting stemness in MCF-10A cells[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 106-109.
[9] M. Englert-Golon, B. Burchardt, R. Słopień, N. Smolarek, S. Sajdak. Ovarian and endometrial cancer after breast cancer - three primary malignancies in a single patient[J]. European Journal of Gynaecological Oncology, 2020, 41(1): 153-154.
[10] A. Markowska, W. Bednarek, R. Jach, A. Czekała, J. Markowska. Uterine fibroids: a new insight into an old problem[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 915-918.
[11] W. Wang, R. Chen, Y. Zhang, K.J. Zou, M.L. Ye, X.H. He, F. Zhang, J. Han, H.Y. Dong. Understanding the molecular link between SPOP gene expression and breast cancer stem cell[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1006-1009.
[12] T. Aizawa, T. Maebayashi, N. Ishibashi, M. Sakaguchi. Bilateral organizing pneumonia after radiotherapy for bilateral synchronous breast cancers: a case report and literature review[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1051-1054.
[13] M. El Homsi, A. Barakat, R. Rammal, M. Haidar. Uterine metastasis from invasive ductal breast carcinoma mimicking fibroid features on MRI and detected by FDG PET/CT: role of SUVmax[J]. European Journal of Gynaecological Oncology, 2019, 40(6): 1079-1082.
[14] A. Markowska, B. Kasprzak, K. Jaszczyńska-Nowinka, J. Markowska. Has the time come for therapy linked to cancer stem cells in ovarian cancer?[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 697-701.
[15] S. Dierckxsens, B. Geerinckx, M.T. Huizing, W.A.A. Tjalma. A review regarding the feasibility and accuracy of a sentinel lymph node biopsy after neo-adjuvant chemotherapy for breast cancer[J]. European Journal of Gynaecological Oncology, 2019, 40(5): 714-721.
No Suggested Reading articles found!